All NTRK-rearranged neoplasms are characterized by immunohistochemical positivity for CD34 and S100 and, molecularly, by fusions of NTRK1, NTRK2, and NTRK3 genes with variable partners; alternative RAF1 and BRAF fusions have also been described. The gene discussed is CD34; the disease is neoplasm.